Characterization and comparison of the responses of equine digital arteries and veins to endothelin-1

American Journal of Veterinary Research

Volumn 64, Issue 11, 2003, Pages 1438-1443

  Katz, Lisa M ^a,b   Marr, Celia M ^a   Elliott, Jonathan ^a  

^a ROYAL VETERINARY COLLEGE   (United Kingdom)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIN 1; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR; ENDOTHELIN B RECEPTOR AGONIST; ENDOTHELIN B RECEPTOR ANTAGONIST; THROMBOXANE; UREA;

ANIMAL EXPERIMENT; ARTICLE; BLOOD VESSEL FUNCTION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIGITAL ARTERY; FORCE TRANSDUCER; HORSE; INTERMETHOD COMPARISON; NONHUMAN; SENSITIVITY ANALYSIS; UREA CYCLE; VASOCONSTRICTION; VENOCONSTRICTION;

ANIMALS; ARTERIES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIN-1; HORSES; MUSCLE CONTRACTION; MUSCLE, SMOOTH, VASCULAR; TOES; VEINS;

ANIMALIA; EQUIDAE; EQUUS CABALLUS;

EID: 0242691893     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.2003.64.1438     Document Type: Article

References (42)

1. Allen D, Clark ES, Moore JN, et al. Evaluation of equine digital Starling forces and hemodynamics during early laminitis. Am J Vet Res 1990;51:1930-1934.
2. Galey FD, Twardock AR, Goetz TE, et al. Gamma scintigraphic analysis of the distribution of perfusion of blood in the equine foot during black walnut (Juglans nigra)-induced laminitis. Am J Vet Res 1990;51:688-695.
3. Hood DM, Amoss MS, Grosenbaugh DA. Equine laminitis: a potential model of Raynaud's phenomenon. Angiology 1990; 41:270-277.
4. Pollitt CC, Molyneux GS. A scanning electron microscopic study of the dermal microcirculation of the equine foot. Equine Vet J 1990;22:79-87.
5. Hunt RJ. The pathophysiology of acute laminitis. Compend Contin Educ Pract Vet 1991;13:401-407.
6. Hood DM, Grosenbaugh DA, Mostafa MB, et al. The role of vascular mechanisms in the development of acute equine laminitis. J Vet Intern Med 1993;7:228-234.
7. Eaton SA, Allen D, Eades SC, et al. Digital Starling forces and hemodynamics during early laminitis induced by an aqueous extract of black walnut (Juglans nigra) in horses. Am J Vet Res 1995;56:1338-1344.
8. Inoue A, Yanagisawa M, Kimura S, et al. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci U S A 1989;86:2863-2867.
9. Arai H, Hori S, Aramori I, et al. Cloning and expression of a cDNA encoding an endothelin receptor. Nature 1990;348: 730-735.
10. Sakurai T, Yanagisawa M, Takuwa Y, et al. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature 1990;348:732-735.
11. Davenport AP. International Union of Pharmacology. XXIX. Update on endothelin receptor nomenclature. Pharmacol Rev 2002;54:219-226.
12. Battistini B, D'Orleans-Juste P, Sirois P. Endothelins: circulating plasma levels and presence in other biologic fluids. Lab Invest 1993;68:600-628.
13. Kohan DE. Endothelins in the normal and diseased kidney. Am J Kidney Dis 1997;29:2-26.
14. Hasegawa K, Fujiwara H, Koshiji M, et al. Endothelin-1 and its receptor in hypertrophic cardiomyopathy. Hypertension 1996;27:259-264.
15. Warner TD. Influence of endothelial mediators on the vascular smooth muscle and circulating platelets and blood cells. Int Angiol 1996;15:93-99.
16. Yanagisawa M, Kiruhara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411-415.
17. Katwa LC, Johnson PJ, Ganjam VK, et al. Expression of endothelin in equine laminitis. Equine Vet J 1999;31:243-247.
18. Rang HP, Dale MM, Ritter JM. The vascular system. In: Pharmacology. 4th ed. Edinburgh, UK: Churchill Livingstone Inc, 1999;281-283.
19. Fleming I, Busse R. Endothelial dysfunction: a novel therapeutic target NO: the primary EDRF. J Mol Cell Cardiol 1999;31:5-14.
20. Russell FD, Davenport AP. Secretory pathways in endothelin synthesis. Br J Pharmacol 1999;126:391-398.
21. Rodman DM, Stelzer TJ, Zamora MR, et al. Endothelin-1 increases the pulmonary microvascular pressure and causes pulmonary edema in salt solution but not blood-perfused rat lungs. J Cardiovasc Pharmacol 1992;20:658-663.
22. Ramaswamy CM, Eades SC, Venugopal CS, et al. Plasma concentrations of endothelin-like immunoreactivity in healthy horses and horses with naturally acquired gastrointestinal tract disorders. Am J Vet Res 2002;63:454-458.
23. Hunt RJ. A retrospective evaluation of laminitis in horses. Equine Vet J 1993;25:61-64.
24. Cohen ND, Parson EM, Seahorn TL, et al. Prevalence and factors associated with development of laminitis in horses with duodenitis/proximal jejunitis: 33 cases (1985-1991). J Am Vet Med Assoc 1994;204:250-254.
25. Miller RC, Mony M, Schini V, et al. Endothelial mediated inhibition of contraction and increase in cyclic GMP levels evoked by alpha-adrenoceptor agonist B-HT 920. Br J Pharmacol 1984;83:903-908.
26. Elliott J, Bryant CE, Soydan J. The role of nitric oxide in the responses of equine digital veins to vasodilator and vasoconstrictor agents. Equine Vet J 1994;26:378-384.
27. Baxter GM, Laskey RE, Tackett RL, et al. In vitro reactivity of digital arteries and veins to vasoconstrictive mediators in healthy horses and in horses with early laminitis. Am J Vet Res 1989; 50:508-517.
28. 1B/1D receptors mediating vasoconstriction of equine digital arteries and veins. Eur J Pharmacol 1998;355:175-187.
29. MacEachern KE, Smith GL, Nolan AM. Methods for the isolation, culture and characterisation of equine pulmonary artery endothelial cells. Res Vet Sci 1997;62:147-152.
30. Venugopal CS, Holmes EP Koch CE, et al. In vitro pharmacologic effect of two endothelin-1 antagonists on equine colonic arteries and veins. Am J Vet Res 2001;62:154-159.
31. Baxter GM. Alterations of endothelium-dependent digital vascular responses in horses given low-dose endotoxin. Vet Surg 1995;24:87-96.
32. Zellers TM, McCormick J, Wu Y. Interaction among ET-1, endothelium-derived nitric oxide, and prostacyclin in pulmonary arteries and veins. Am J Physiol 1994;267:H139-H147.
33. Wiley KE, Davenport AP. Nitric oxide-mediated modulation of the endothelin-1 signaling pathway in the human cardiovascular system. Br J Pharmacol 2001:132:213-220.
34. Yokokawa K, Kohno M, Yasunari K, et al. Endothelin-3 regulates endothelin-1 production in cultured human endothelial cells. Hypertension 1991;18:304-315.
35. Cao WB, Zeng ZP, Zhu YJ, et al. Inhibition of nitric oxide synthesis increases the secretion of endothelin-1 in vivo and in cultured endothelial cells. Chin Med J (Engl) 1994;107:822-826.
36. Ahlborg G, Lundberg JM. Nitric oxide-endothelin-1 interaction in humans. J Appl Physiol 1997;82:1593-1600.
37. Warner TD. Relationships between the endothelin and nitric oxide pathways. Clin Exp Pharmacol Physiol 1999;26:247-252.
38. Ishikawa K, Ihara M, Noguchi K, et al. Biochemical and pharmacological profile of a potent and selective endothelin B-receptor antagonist, BQ-788. Proc Natl Acad Sci U S A 1994;91: 4892-4896.
39. Okada M, Nishikibe M. BQ-788, a selective endothelin ET(B) receptor antagonist. Cardiovasc Drug Rev 2002;20:53-66.
40. Ishiguro S, Kawase J, Miyamoto A, et al. Endothelin receptor mediating contraction of isolated bovine coronary artery. J Vet Pharmacol Ther 2001;24:203-208.
41. Schoeffter P, Randriantsoa A. Differences between endothelin receptors mediating contraction of guinea-pig aorta and pig coronary artery. Eur J Pharmacol 1993;249:199-206.
42. B receptors mediate vascular smooth muscle contraction. Br J Pharmacol 1992;107:858-860.